Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic takes Valiant thoracic graft to EU:

This article was originally published in Clinica

Executive Summary

Medtronic has launched for sale in Europe its Valiant thoracic stent graft and accompanying Xcelerant delivery system for the minimally invasive treatment of diseases of the thoracic aorta. The graft is more conformable than earlier generation devices, and the new delivery system enables precise transluminal deployment of the implant, said the firm. It also offers more size and end configuration options, giving physicians a greater opportunity of matching the graft to the patient's anatomy. The device is available in covered graft lengths of up to 20cm "for maximum lesion coverage and the use of fewer graft segments to complete procedures", said the firm. Every year in Europe, descending thoracic aortic lesions are diagnosed in around 16,000 patients, many of whom are at risk if they undergo traditional open surgery, Medtronic added.

You may also be interested in...



Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.

Topics

UsernamePublicRestriction

Register

MT054795

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel